BetterLife Pharma Appoints LifeSci Advisors as Investor Relations Firm

What happened

BetterLife Pharma Inc. has retained LifeSci Advisors to support its investor relations and corporate communications, following Canadian Securities Exchange policies. The company is developing BETR-001 for chronic cluster headache and chronic migraine and targets an Investigational New Drug application in the first quarter of 2027.

Confirmed

Global impact / market context

BetterLife is a small public biotechnology company with shares quoted on the OTCQB market and listed in Frankfurt. Hiring an investor relations firm is meant to widen awareness among investors as the company moves BETR-001 toward a planned regulatory filing and clinical development in 2027.

Confirmed

Small drug developers often rely on outside investor relations help to reach more potential shareholders, which can improve how easily their shares trade. BetterLife also recently added headache experts to its scientific advisory board and raised money through a financing led by Deep Track Capital, steps that may support investor confidence.

Analyst inference

What to watch

1. Watch whether BetterLife submits its Investigational New Drug application for BETR-001 in the first quarter of 2027, a key regulatory step before testing the drug in people. Confirmed
2. Watch whether LifeSci Advisors expands BetterLife's outreach to new investors and improves awareness of the company's story ahead of planned clinical development in 2027. Proposed
3. Watch the company's cash position and spending after its financing led by Deep Track Capital, since drug development costs can use cash quickly before any revenue arrives. Analyst inference

Evidence

• newsfilecorp.com